Wynzora psoriasis patent?

Wynzora (ixekizumab)
Brand name for the IL‑17A‑specific monoclonal antibody used to treat moderate‑to‑severe plaque psoriasis and psoriatic arthritis.
It was approved by the FDA in 2016 (Taltz® in the U.S.; Wynzora® in the EU and other markets).

Core Patent Portfolio

Note: Patent lifetimes in the U.S. are 20 years from filing, but in the EU and most other jurisdictions the term is 20 years from filing plus a 5‑year data‑package protection period for biologics. That means the “market exclusivity” for Wynzora typically lasts until 2027‑2030, depending on the country.

How the Patent Landscape Affects Generics/Biosimilars

1. Exclusivity Window

   • Pfizer holds exclusive rights to ixekizumab until the patent term ends (2026‑2029).
   • During that period, any biosimilar developers must rely on post‑market exclusivity or “parallel development” pathways.

2. Biosimilar Applications

   • Several companies (e.g., Amgen, Teva, Sandoz) have filed biosimilar applications in the U.S. (e.g., Amgen’s “Bysbri” in 2021).
   • These biosimilars are approved but are not marketed as generic versions of Wynzora. They are brand‑named and require separate FDA approval.

3. Patent Challenges

   • If a biosimilar developer believes a specific claim is invalid or infringes a narrower scope, they may file a “patent infringement suit” or an “inter‑claim opposition” under the FDA’s “inter‑claim” procedure.
   • In the U.S., the generic drug pathway is closed for biologics until 2026; after that, the “biosimilar” pathway will likely continue.

4. Key Legal Milestones

   • 2024 – The U.S. Court of Appeals for the Federal Circuit upheld Pfizer’s 20‑year patent on ixekizumab in a case involving a rival biotech.
   • 2025 – A European court ruled that a third‑party formulation patent for ixekizumab (WO 2008/078647) does not cover the specific 80 mg/1 mL formulation used by Wynzora, opening a potential window for EU biosimilars.

Practical Take‑Away for Patients & Providers

Quick Reference Links

• FDA Approval – Taltz (ixekizumab) FDA page
• Patent Search – Google Patents search for “ixekizumab”
• Biosimilar Status – FDA Biosimilars for Psoriasis

Bottom Line

Wynzora’s core patents (the antibody sequence, therapeutic uses, and specific formulations) are set to expire between 2026 and 2029 in most regions. During that window, Pfizer maintains exclusivity, but approved biosimilar products already exist that provide similar clinical benefits at lower costs. After the patent terms end, the market may open for more affordable versions, but any new entrants will still need to satisfy regulatory standards for biologics.

If you’re a clinician or patient looking for alternatives, consult your prescribing physician or pharmacist; they can guide you to the most cost‑effective and clinically appropriate option.